RxDoctor Payments DataLook up a doctor →

Amy Cleveland, MD

Hematology & Oncology · Hot Springs, ARNPI 1871767152

Payments from drug & device makers

$81,812in general payments, 2019–2025

Across 554 payments — averaging $147.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tolmar, Inc.$68K
  • Verastem, Inc.$5K
  • Novartis$971
  • Merck$560
  • Pfizer$512
  • Bristol Myers Squibb$486
  • plus $7K from 53 others

What the payments were for

  • Food & beverage$8,87198%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tolmar, Inc.19$67,774
Verastem, Inc.1$5,000
Novartis55$971
Merck34$560
Pfizer37$512
Bristol Myers Squibb38$486
AstraZeneca(2 entities)25$405
GSK20$372
AbbVie19$369
E.r. Squibb & Sons, L.L.C.23$337
Lilly USA, LLC19$328
Gilead(2 entities)18$302
Amgen18$289
Eisai Inc.15$271
Johnson & Johnson(2 entities)18$270
Daiichi Sankyo Inc.11$246
Karyopharm Therapeutics Inc.11$246
Incyte Corporation13$217
Genentech USA, Inc.16$216
Pharmacyclics LLC, An Abbvie Company12$189
Ipsen Biopharmaceuticals, Inc10$187
Astellas Pharma US Inc9$163
Servier Pharmaceuticals LLC1$162
Sanofi8$161
EMD Serono, Inc.10$152
Seagen Inc.10$145
Bayer7$135
Exelixis Inc.9$130
Array Biopharma Inc5$105
Puma Biotechnology, Inc.6$103
Tesaro, Inc.3$93
ADC Therapeutics America, Inc.5$87
Rigel Pharmaceuticals, Inc.5$85
Takeda Pharmaceuticals U.S.A., Inc.4$63
AVEO Pharmaceuticals, Inc.3$61
G1 Therapeutics, Inc.3$45
Beigene USA, Inc.3$45
Pharmacosmos Therapeutics Inc.3$44
Sumitomo Pharma America, Inc.2$42
Morphosys, US Inc.2$42
Regeneron Healthcare Solutions, Inc.2$35
Foundation Medicine, Inc.2$32
Dova Pharmaceuticals2$31
Myovant Sciences Inc.2$29
Epizyme, Inc.2$28
Recordati_rare_diseases_inc.1$25
Apellis Pharmaceuticals, Inc.1$23
CTI Biopharma Corp.1$22
Sirtex Medical Inc1$21
Adaptive Biotechnologies Corporation1$21
Heron Therapeutics, Inc.1$19
Dendreon Pharmaceuticals LLC1$19
Jazz Pharmaceuticals Inc.1$16
Sobi, Inc1$16
Beone Medicines USA, Inc.1$15
Clovis Oncology, Inc.1$14
Spectrum Pharmaceuticals Inc.1$13
AMAG Pharmaceuticals, Inc.1$12
Teva Pharmaceuticals USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,812 in reported general payments places this provider in the 70th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$4,694,606
Medicare patients
880
Services billed
184,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate46$557,974
CalquenceAcalabrutinib Maleate37$539,875
XtandiEnzalutamide32$459,584
ImbruvicaIbrutinib25$409,175
IbrancePalbociclib23$344,463
RevlimidLenalidomide17$288,644
Abiraterone Acetate47$207,123
Lenalidomide15$196,647
NubeqaDarolutamide11$147,352
TrazimeraTrastuzumab-Qyyp14$55,960
Imatinib Mesylate29$54,985
EliquisApixaban74$43,752
ZarxioFilgrastim-Sndz14$15,633
Anastrozole202$3,154
Ondansetron OdtOndansetron87$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$217$557,97446 claims
AstraZenecaCalquence$405$539,87537 claims
Astellas Pharma US IncXtandi$163$459,58432 claims
PfizerIbrance, Trazimera, Eliquis$512$444,176111 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$189$409,17525 claims
Bristol Myers SquibbRevlimid$486$288,64417 claims
BayerNubeqa$135$147,35211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →